Fig. 4

Targeted inhibition of Sirt6 by OSS_128167 exerted anti-tumor activity in DLBCL cells. a OSS_128167 decreased cell viability in primary DLBCL cells. b OSS_128167 decreased cell viability in DLBCL cell lines. c OSS_128167 induced fast onset cell apoptosis in primary DLBCL cells and cell lines. d OSS_128167 induced G2/M cell cycle arrest in DLBCL cells. e LY1 cells were injected subcutaneously into the SCID beige mice. Eight days after, the mice were treated with intraperitoneal injection of either OSS_128167 (80 mg/kg) or a control vehicle every 2 days for 2 weeks. Decreased tumor growth were observed in mice treated with OSS_128167 in contrast to the vehicle control group (n = 4 per group). f H&E and IHC staining with Sirt6 and Ki-67 were performed. Bar = 50 μm. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001